American Heart Journal
Volume 151, Issue 1 , Pages 84-91, January 2006

Overview of acute decompensated heart failure in Argentina: Lessons learned from 5 registries during the last decade

  • Eduardo R. Perna, MD

      Affiliations

    • Instituto de Cardiologia “Juana F. Cabral,” Corrientes, Argentina
    • Corresponding Author InformationReprint requests: Eduardo R. Perna, MD, Instituto de Cardiología “Juana F. Cabral,” Bolivar 1334, Corrientes 3.400, Argentina.
  • ,
  • Alejandro Barbagelata, MD

      Affiliations

    • Hospital Italiano, Buenos Aires, Argentina
  • ,
  • Liliana Grinfeld, MD

      Affiliations

    • Hospital Italiano, Buenos Aires, Argentina
  • ,
  • Marta García Ben, PhD

      Affiliations

    • Universidad de Buenos Aires, Buenos Aires, Argentina
  • ,
  • Juan P. Címbaro Canella, MD

      Affiliations

    • Instituto de Cardiologia “Juana F. Cabral,” Corrientes, Argentina
  • ,
  • Pablo A. Bayol, MD

      Affiliations

    • Instituto de Cardiologia “Juana F. Cabral,” Corrientes, Argentina
  • ,
  • Alvaro Sosa Liprandi, MD

      Affiliations

    • Instituto de Alta Complejidad Médica, Buenos Aires, Argentina

Received 16 December 2004; accepted 1 March 2005.

Background

The acute decompensated heart failure (ADHF) is not as well characterized as the chronic phase, particularly in Latin American countries. Thus, the aim of this overview was to describe the clinical profile, treatment, and inhospital course of ADHF during the last decade in Argentina.

Methods

Results obtained from 5 Argentinean prospective and multicenter registries, involving 2974 patients admitted for ADHF, were assessed. These registries were performed and published between 1992 and 2004.

Results

The mean age was 65 to 70 years, and nearly 40% were female. Coronary artery disease was the main etiology in nearly 30% of the patients. Between 1992 and 2004, the use of angiotensin-converting enzyme inhibitors increased from 29.9% to 53.4% before admission and from 48.5% to 69.3% before discharge; the use of β-blockers rose from 4.2% to 33.2% at admission and from 2.5% to 42.4% at predischarge (all P < .0001). Inhospital mortality rates in the first to the fifth registries were 12.1%, 4.6%, 10.5%, 8.9%, and 4.7% (P [trend] = .006). However, there were 98 (7.7%) deaths among 1272 patients before 2002, compared with 129 (7.6%) among 1702 since 2002 (P = .9).

Conclusions

The clinical profile of this largest sample of ADHF reported from a Latin American country is different from that observed in clinical trials and comparable to registries worldwide. Although an improvement in the use of recommended drugs was observed in the last decade, the average mortality has not changed. These findings might have implications in the design of multinational clinical trials.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0002-8703(05)00260-7

doi:10.1016/j.ahj.2005.03.010

American Heart Journal
Volume 151, Issue 1 , Pages 84-91, January 2006